Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

Tecfidera Slow-Titration Study

Phase 3

Terminated

Conditions: Multiple Sclerosis

Interventions: Drug: dimethyl fumarate

First Posted Date: 2015-04-28

Last Posted Date: 2017-05-05

Lead Sponsor: Biogen

Target Recruit Count: 62

Registration Number: NCT02428231

Locations: 🇮🇹
Research Site, Montichiari, Italy

A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome

Completed

Conditions: Sjögren's Syndrome
Healthy
Sicca Syndrome

Interventions: Procedure: Biopsy

First Posted Date: 2015-04-21

Last Posted Date: 2018-01-19

Lead Sponsor: Biogen

Target Recruit Count: 100

Registration Number: NCT02422407

Locations: 🇺🇸
Research Site, Dallas, Texas, United States

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: dimethyl fumarate
Drug: Placebo
Drug: montelukast

First Posted Date: 2015-04-07

Last Posted Date: 2020-03-31

Lead Sponsor: Biogen

Target Recruit Count: 102

Registration Number: NCT02410278

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

Phase 2

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: dimethyl fumarate

First Posted Date: 2015-04-07

Last Posted Date: 2017-10-23

Lead Sponsor: Biogen

Target Recruit Count: 22

Registration Number: NCT02410200

Locations: 🇹🇷
Research Site, Ankara, Turkey

Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: natalizumab

First Posted Date: 2015-03-12

Last Posted Date: 2018-09-13

Lead Sponsor: Biogen

Target Recruit Count: 48

Registration Number: NCT02386566

Locations: 🇨🇭
Research Site, Zurich, Switzerland
🇨🇭
Research site - private practice, Luzern, Switzerland

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

Phase 2

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Drug: Nusinersen

First Posted Date: 2015-03-12

Last Posted Date: 2025-01-13

Lead Sponsor: Biogen

Target Recruit Count: 25

Registration Number: NCT02386553

Locations: 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Nemours Children's Hospital, Orlando, Orlando, Florida, United States

and more 22 locations